• Selective: Operates only in high shear blood flow as in a stenosis
• Improved Safety: Reduces the risk of bleeding complications from slow bleeds

• Algorithm specifically prepared to search entire genomes to identify off-target cleavage sites and design optimal primers for TALENs and ZFNs
• Available as a simple, user-friendly web-based tool; no extraordinary bioinformatics or biochemical skill required
• Capable of analyzing TALEN and ZFN sequences targeting human, rat, mouse, zebrafish, arabidopsis, yeast, D melanogaster,

• Cost efficient – fast localization, characterization, and control minimize costs
• Does not require MRI – high-resolution mapping eliminates need for MRI imaging
• Fast operation – operation can be performed in minutes

This technology can be used in the development of yeast-based syntheses of plant alkaloids, or any other biosynthetic pathway that uses 5-hydroxytryptohan or L-DOPA as precursors. It can be used for the synthesis of compound monoterpene indole alkaloids derived from strictosidine (e.g. quinine, camptothecin, ajmalicine, serpentine, vinblastine and vincristine) or benzylisoquinoline alkaloids derived from dopamine (e.g. berberine and morphine).

• Apatamers have unique secondary structure, allowing them to bind with high specificity and affinity to a specific target
• Utilizes intrinsic double stranded DNA break (DSB) and repair system, enabling targeted delivery of exogenous DNA in all eukaryotic cell types
• AGT development could lead to enhancement of gene editing technologies and ultimately disease-targeted therapy

• Viable, cellular micro-environments requiring precise control are achieved using hydrogel microspheres with diameter sizes ranging from 10-1000 micrometers
• A protective, semi-permeable capsule encases the cells and biomolecules
• Release rates of encapsulated biomolecules or drugs are controlled by adjusting the polymer parameters used to fabricate hydrogel microspheres

• Cheaper and faster to manufacture- production only involves synthesis of ligands, nanoparticles, and nano-antibodies; it does not involve cell-lines or animal work
• More effective- better accumulation and penetration is achieved due to the nanoparticle design
• Better for patients- dosage to achieve therapeutic efficacy is reduced and can lower the price, duration, and frequency of treatment

• Novel group of RNA interference targets with utility in basic research and practical applications
• Non-coding interference RNAs (nciRNAs) offer an efficient mechanism of mortality in eukaryotic cells
• Highly specific targeting of pests or pathogens

• Inexpensive, rapid, adaptable, and reliable in vivo system for sequestering and packaging of iRNAs
• Flexible, for long or short, single-stranded or double-stranded iRNA of any sequence
• Efficiently delivers iRNA to biological targets; VLP-iRNAs are readily taken up by many cell types

• Higher cell densities
• Protection from high shear production environments
• Reduced initial and operating cost

• Novel structure with high binding affinity for DHFR
• Demonstrated growth inhibition of numerous pathogens
• Demonstrated antibacterial activity for mulit-drug resistant strains of E. coli, methicillin-resistant S. aureus (MRSA), vancomycin-resistant E. faecalis & antifungal activity against amphotericin–resistant Candida albicans

• First discovery of small-molecules binding to the central catalytic domain of NGly1
• Could be used to treat the inherited genetic disorder resulting from NGly1 deficiency

• Low cost and effective production method
• Maintains protein structure and enzymatic activity and maximizes the amount of protein to be delivered
• Preserves bioactivity

• Prevent various infections currently impacting patients due to bacteria formation on medical tubes.
• Solution that can be utilized with existing medical tubes.
• Does not leach any materials from the tubing surface.

• Accelerated wound healing and tissue regeneration through drug-eluting sutures
• Increased drug loading and sustained drug delivery due to the interconnected porosity feature of the sutures
• Release of cytokines, extracellular matrix proteins, anti-inflammatory, anti-microbial, and pain management drugs to injury site

• Novel – No present technology exists
• Versatile – Can be adapted to suit a variety of diseases, human and animal
• Targeted – Antigen-binding qualities within the B cell allow for highly specific therapies